10.5061/DRYAD.69P8CZ8ZW
Derraz, Imad
0000-0003-0632-3399
Hôpital Gui De Chauliac
Cagnazzo, Federico
Hôpital Gui De Chauliac
Gaillard, Nicolas
Hôpital Gui De Chauliac
Morganti, Riccardo
University of Pisa
Dargazanli, Cyril
Hôpital Gui De Chauliac
Ahmed, Raed
Hôpital Gui De Chauliac
Lefevre, Pierre-Henri
Hôpital Gui De Chauliac
Riquelme, Carlos
Hôpital Gui De Chauliac
Mourand, Isabelle
Hôpital Gui De Chauliac
Gascou, Gregory
Hôpital Gui De Chauliac
Bonafe, Alain
Hôpital Gui De Chauliac
Arquizan, Caroline
Hôpital Gui De Chauliac
Costalat, Vincent
Hôpital Gui De Chauliac
Microbleeds, cerebral hemorrhage, and functional outcome after
endovascular thrombectomy
Dryad
dataset
2020
2021-12-28T00:00:00Z
2021-12-28T00:00:00Z
en
112741 bytes
2
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
Objective—To determine whether the presence, number, and distribution of
cerebral microbleeds (CMBs) on pretreatment MRI scans are associated with
an increased risk of intracerebral hemorrhage (ICH) or poor functional
outcome following endovascular thrombectomy (EVT) for acute
ischemic stroke (AIS). Methods—We analyzed prospectively collected data of
consecutive patients treated by EVT for AIS, in a comprehensive stroke
center where MRI is the first-line pretreatment imaging. Neuroradiologists
blinded to clinical data rated CMBs on T2* sequence using a validated
scale. We investigated associations of pre-treatment CMB presence, burden
(1, 2–4, and ≥5), and presumed pathogenesis with ICH and poor 3-month
functional outcome (modified Rankin score >2). Results—Among 513
patients, 281 (54.8%) had a poor outcome and 89 (17.3%) had ≥1 CMBs. A
total of 190 (37%) patients experienced ICH, in which 66 (12.9%) were
symptomatic. CMB burden was associated with worse outcome in a univariable
analysis (odds ratio [OR], 1.18; 95% confidence interval [CI], 1.03–1.36
per 1-CMB increase; P=0.02), but significance was lost after adjustment
for age, sex, baseline stroke severity, hypertension, diabetes mellitus,
atrial fibrillation, prior antithrombotic medication, intravenous
thrombolysis, and reperfusion status (OR, 1.05; 95% CI, 0.92–1.20 per
1-CMB increase; P=0.50). Results remained nonsignificant when taking into
account CMB location or presumed underlying vasculopathy. CMB presence,
burden, location, nor presumed underlying vasculopathy was independently
associated with ICH. Conclusions—Poor outcome or ICH was not associated
with CMB presence or burden on pre–EVT MRI after adjustment for
confounding factors. Excluding such patients from reperfusion therapies is
unwarranted.